目的 評(píng)估二甲雙胍治療2型糖尿病患者罹患肝癌的風(fēng)險(xiǎn)。方法 從PubMed、Embase、中國(guó)期刊全文數(shù)據(jù)庫(kù)（CNKI）、維普全文數(shù)據(jù)庫(kù)（VIP）萬(wàn)方等數(shù)據(jù)庫(kù)獲得關(guān)于二甲雙胍與糖尿病患者罹患肝癌風(fēng)險(xiǎn)的相關(guān)研究，評(píng)價(jià)二甲雙胍治療糖尿病過(guò)程中，患者罹患肝癌的風(fēng)險(xiǎn)，檢索時(shí)限為從建庫(kù)至2017年12月。結(jié)果 共納入11篇相關(guān)文獻(xiàn)，其中病例對(duì)照研究8篇，隊(duì)列研究3篇；共計(jì)123 412例患者，其中實(shí)驗(yàn)組78 817例，對(duì)照組44 595例。病例對(duì)照研究Meta-分析結(jié)果顯示，與其他降糖藥相比，二甲雙胍治療可使2型糖尿病患者肝癌發(fā)病風(fēng)險(xiǎn)降低42%［RR=0.58，95% CI（0.52，0.65），P=0.000 01］；隊(duì)列研究Meta-分析結(jié)果則顯示，二甲雙胍治療可使2型糖尿病患者肝癌發(fā)病風(fēng)險(xiǎn)降低47%［RR=0.53，95% CI（0.13，2.21），P=0.38］。結(jié)論 二甲雙胍治療可降低2型糖尿病患者罹患肝癌的風(fēng)險(xiǎn)。

Objective To evaluate the risk of morbidity of liver cancer in type 2 diabetes treated with metformin. Methods The cohort studies and case-control studies in evaluating the effect of metformin on liver cancer in type 2 diabetes were researched from PubMed, Embase, CNKI, VIP and Wanfang Data until December 2016. Results A total of 11 articles were included, eight of which were case-control studies and three were cohort studies. A total of 123 412 patients, including 78 817 patients in the experimental group and 44 595 cases in the control group. Meta-analysis of case-control studies showed that metformin treatment can reduce the risk of morbidity of liver cancer in type 2 diabetes by 42%[RR=0.58, 95%CI(0.52, 0.65), P=0.000 01] compared with other antidiabetic drugs; the results from the cohort studies showed that metformin therapy can reduce the risk of morbidity of liver cancer in type 2 diabetes patients by 47%[RR=0.53, 95%CI(0.13, 2.21), P=0.38] compared with those with other antidiabetic drugs. Conclusion Metformin therapy can reduce the risk of morbidity of liver cancer in patients with type 2 diabetes.

四川省教育廳重點(diǎn)項(xiàng)目（16ZA0178）；瀘州市科技局項(xiàng)目［2016-R-70（11/24）］